Psyence Biomedical (Psyence Biomedical) Buyback Yield % : 0.00 (As of Apr. 30, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Psyence Biomedical's current buyback yield was 0.00%.

Psyence Biomedical Buyback Yield % Historical Data

The historical data trend for Psyence Biomedical's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Buyback Yield % Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Buyback Yield %

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Buyback Yield %	-	-	-

Competitive Comparison of Psyence Biomedical's Buyback Yield %

For the Biotechnology subindustry, Psyence Biomedical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Buyback Yield % falls into.

Psyence Biomedical Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Psyence Biomedical's Buyback Yield for the fiscal year that ended in Mar. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	0
	=	N/A%

Psyence Biomedical's annualized Buyback Yield for the quarter that ended in Mar. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	1	/	0
	=	N/A%

In calculating the annualized data, the Repurchase of Stock and Issuance of Stock data used here is one times the annual (Mar. 2023) data.

Psyence Biomedical Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024